Responses to Crizotinib therapy in five patients with non-small-cell lung cancer who tested FISH negative and Ventana immunohistochemistry positive for ALK fusions
| Autor: | Chong-Mei Zhu, Jing Zeng, Fang Wang, Suxia Lin, Jin-Lin Huang, Wei-Qiang Chen, Qi-Tao Huang, Jie-Tian Jin, Xiao-Mei Li, Jia-Bin Lu |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Lung Neoplasms Pyridines medicine.medical_treatment Adenocarcinoma 03 medical and health sciences 0302 clinical medicine Crizotinib Carcinoma Non-Small-Cell Lung hemic and lymphatic diseases Internal medicine medicine Humans Anaplastic Lymphoma Kinase Lung cancer In Situ Hybridization Fluorescence Gene Rearrangement Pharmacology Chemotherapy business.industry Receptor Protein-Tyrosine Kinases General Medicine Gene rearrangement medicine.disease Immunohistochemistry Radiation therapy 030104 developmental biology 030220 oncology & carcinogenesis Pyrazoles Molecular Medicine Fish business medicine.drug |
| Zdroj: | Personalized Medicine. 14:99-107 |
| ISSN: | 1744-828X 1741-0541 |
| DOI: | 10.2217/pme-2016-0080 |
| Popis: | Aim: Although immunohistochemistry (IHC) and reverse transcription-PCR can detect ALK rearrangements, the ALK break-apart FISH assay is currently considered the standard method. Materials & methods: Five patients with advanced non-small-cell lung cancer, who had an ALK-negative FISH result that was later confirmed as positive by the Ventana IHC assay, were studied. Four had previously received chemotherapy or radiotherapy. All five were subsequently treated with Crizoitinib 250 mg twice daily. Results & conclusion: Four patients had a partial response to Crizotinib and one had stable disease. IHC is an efficient technique for diagnosing ALK rearrangements in patients with non-small-cell lung cancer, and may serve as an alternative to FISH in clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|